Drugs Made in America Acquisition II FY26 Q2 net income turns to profit at $4.4 million

• Drugs Made in America Acquisition II posted net income of $4.4 million for the quarter ended June 30, 2026.
• General and administrative costs totaled $112,227, offset by $4.51 million of interest income from the trust account.
• Six-month net income rose to $8.73 million, reflecting $8.95 million of trust interest income and a $30,000 credit-loss recovery.
• Cash was $174,974 at June 30, 2026, up from $223 at Dec. 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made in America Acquisition II Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-090017), on August 14, 2026, and is solely responsible for the information contained therein.